Table 2.
Demographics of the efficacy and safety populations
| Demographics | Primary efficacy population (n = 49) | Safety analysis population (n = 71) |
|---|---|---|
| Median age (range), years | 57 (18–72) | 58 (18–73) |
| Age group, years | ||
| <65 | 43 (88%) | 58 (82%) |
| ≥65 | 6 (12%) | 13 (18%) |
| Sex | ||
| Male | 23 (47%) | 35 (49%) |
| Female | 26 (53%) | 36 (51%) |
| Race | ||
| White | 45 (92%) | 66 (93%) |
| Black | 2 (4%) | 3 (4%) |
| Asian | 2 (4%) | 2 (3%) |
| Ethnicity | ||
| Hispanic/Latino | 7 (14%) | 9 (13%) |
| Not Hispanic/Latino | 41 (84%) | 60 (85%) |
| Not reported | 1 (2%) | 2 (3%) |
| Diagnosis | ||
| Acute leukemia/MDS | 32 (65%) | 48 (68%) |
| Lymphoma/CLL | 7 (14%) | 12 (17%) |
| Other | 10 (20%) | 11 (15%) |
| Donor | ||
| Matched related | 17 (35%) | 23 (32%) |
| Matched unrelated | 20 (41%) | 32 (45%) |
| Mismatched unrelated | 6 (12%) | 9 (13%) |
| Haploidentical | 5 (10%) | 6 (8%) |
| Mismatched cord blood | 1 (2%) | 1 (1%) |
| Stem cell type | ||
| Apheresis | 39 (80%) | 57 (80%) |
| Marrow | 9 (18%) | 13 (18%) |
| Cord blood | 1 (2%) | 1 (1%) |
Abbreviations: CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome.